Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Across preclinical research, BPC-157 has been reported to have a favorable tolerability profile: a 2021 Frontiers in Pharmacology review noted no reported toxicity in animal studies, with the LD1 (lethal dose for 1% of animals) not reached
GHK-Cu can be used alone or alongside conventional therapies (like minoxidil or PRP)
As the body only absorbs the B12 it needs, there is no risk of overdose
Emerging preclinical and early clinical studies in humans highlight the potential of BPC-157 and TB-500
It provides broader context for Dihexa's mechanism of action and its position within the angiotensin IV receptor research field, evaluating both the strength and limitations of the existing preclinical evidence base
Peptides support but do not replace appropriate medical evaluation
